FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending July 2010
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

 

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
I give below details of an increase in interests in Ordinary shares in GlaxoSmithKline plc purchased at a price of £11.75 per share on 13 July 2010, and
Ordinary share ADRs
in GlaxoSmithKline plc
purchased at a price of $34.12 per ADR
on 13 July 2010, in respect of the personal holdings of the under-mentioned persons
following the re-investment of the dividend paid to shareholders on 8 July 2010.
 


Ordinary shares
ADRs
Dr M M Slaoui
159.45
159.57
Mrs C E Bruck Slaoui
32.71
5.60
Mr J M Clarke
401.99

Mr M Dunoyer
192.20

Mr E J Gray
226.97

Mr W C Louv

124.50
Mr D J Phelan

304.25
Dr D Pulman

187.24
Mr D S Redfern
122.89

Mr J R Stéphenne
594.80

Ms C Thomas
93.02

Mr P J T Vallance
55.64



 
The Company was advised of this information on 14 July 2010.
 
This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
S M Bicknell
Company Secretary
 
14 July 2010

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: July 14, 2010

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc